Cardiology Research and Practice meta-analysis,” American Journal of Medicine, vol. 117, no. 12, pp. 938–947, 2004. [86] S. M. Bagshaw and W. A. Ghali, “Acetylcysteine for pre- vention of contrast-induced nephropathy after intravascular angiography: a systematic reveiw and meta-analysis,” BMC Medicine, vol. 2, article no. 38, 2004. [87] M. Maioli, A. Toso, M. Leoncini et al., “Sodium bicar- bonate versus saline for the prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention,” Journal of the Ameri- can College of Cardiology, vol. 52, no. 8, pp. 599–604, 2008. [88] G. Patti, A. Nusca, M. Chello et al., “Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention,” American Journal of Cardiology, vol. 101, no. 3, pp. 279–285, 2008. [89] N. Attallah, L. Yassine, J. Musial, J. Yee, and K. Fisher, “The potential role of statins in contrast nephropathy,” Clinical Nephrology, vol. 62, no. 4, pp. 273–278, 2004. [90] S. Khanal, N. Attallah, D. E. Smith et al., “Statin therapy reduces contrast-induced nephropathy: an analysis of con- temporary percutaneous interventions,” American Journal of Medicine, vol. 118, no. 8, pp. 843–849, 2005. [91] A. Toso, M. Maioli, M. Leoncini et al., “Usefulness of atorvas- tatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease,” American Journal of Cardiology, vol. 105, no. 3, pp. 288–292, 2010. [92] J. Xinwei, F. Xianghua, Z. Jing et al., “Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coro- nary syndrome undergoing percutaneous coronary interven- tion,” American Journal of Cardiology, vol. 104, no. 4, pp. 519– 524, 2009. [93] A. Kapoor, N. Sinha, R. K. Sharma et al., “Use of dopamine in prevention of contrast induced acute renal failure—a randomised study,” International Journal of Cardiology, vol. 53, no. 3, pp. 233–236, 1996. [94] M. Gare, Y. S. Haviv, A. Ben-Yehuda et al., “The renal eﬀect of low-dose dopamine in high-risk patients undergoing coronary angiography,” Journal of the American College of Cardiology, vol. 34, no. 6, pp. 1682–1688, 1999. [95] A. S. Abizaid, C. E. Clark, G. S. Mintz et al., “Eﬀects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with pre- existing renal insuﬃciency,” American Journal of Cardiology, vol. 83, no. 2, pp. 260–263, 1999. [96] J. A. Tumlin, A. Wang, P. T. Murray, and V. S. Mathur, “Fenoldopam mesylate blocks reductions in renal plasma ﬂow after radiocontrast dye infusion: a pilot trial in the pre- vention of contrast nephropathy,” American Heart Journal, vol. 143, no. 5, pp. 894–903, 2002. [97] G. W. Stone, P. A. McCullough, J. A. Tumlin et al., “Fenoldopam mesylate for the prevention of contrast- induced nephropathy: a randomized controlled trial,” Journal of the American Medical Association, vol. 290, no. 17, pp. 2284–2291, 2003. [98] P. S. Teirstein, M. J. Price, V. S. Mathur et al., “Diﬀerential eﬀects between intravenous and targeted renal delivery of fenoldopam on renal function and blood pressure in patients undergoing cardiac catheterization,” American Journal of Cardiology, vol. 97, no. 7, pp. 1076–1081, 2006. [99] W. Huber, K. Ilgmann, M. Page et al., “Eﬀect of theophylline on contrast material-induced nephropathy in patients with 11 chronic renal insuﬃciency: controlled, randomized, double- blinded study,” Radiology, vol. 223, no. 3, pp. 772–779, 2002. [100] A. Kapoor, S. Kumar, S. Gulati, S. Gambhir, R. S. Sethi, and N. Sinha, “The role of theophylline in contrast-induced nephropathy: a case-control study,” Nephrology Dialysis Transplantation, vol. 17, no. 11, pp. 1936–1941, 2002. [101] C. M. Erley, S. H. Duda, D. Rehfuss et al., “Prevention of radiocontrast-media-induced nephropathy in patients with pre-existing renal insuﬃciency by hydration in combination with the adenosine antagonist theophylline,” Nephrology Dialysis Transplantation, vol. 14, no. 5, pp. 1146–1149, 1999. [102] H.-H. Neumayer, W. Junge, A. Kufner, and A. Wenning, “Prevention of radiocontrast-media-induced nephrotoxicity by the calcium channel blocker nitrendipine: a prospective randomised clinical trial,” Nephrology Dialysis Transplanta- tion, vol. 4, no. 12, pp. 1030–1036, 1989. [103] M. Carraro, W. Mancini, M. Artero et al., “Dose eﬀect of nitrendipine on urinary enzymes and microproteins fol- lowing non-ionic radiocontrast administration,” Nephrology Dialysis Transplantation, vol. 11, no. 3, pp. 444–448, 1996. [104] Z. Khoury, J. R. Schlicht, J. Como et al., “The eﬀect of prophylactic nifedipine on renal function in patients administered contrast media,” Pharmacotherapy, vol. 15, no. 1 I, pp. 59–65, 1995. [105] M. H. Sketch Jr., A. Whelton, E. Schollmayer et al., “Prevention of contrast media-induced renal dysfunction with prostaglandin E1: a randomized, double-blind, placebo- controlled study,” American Journal of Therapeutics, vol. 8, no. 3, pp. 155–162, 2001. [106] K. Spargias, E. Alexopoulos, S. Kyrzopoulos et al., “Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention,” Circulation, vol. 110, no. 18, pp. 2837–2842, 2004. [107] B. R. C. Kurnik, R. L. Allgren, F. C. Center, R. J. Solomon, E. R. Bates, and L. S. Weisberg, “Prospective study of atrial natriuretic peptide for the prevention of radiocontrast- induced nephropathy,” American Journal of Kidney Diseases, vol. 31, no. 4, pp. 674–680, 1998. [108] B. Vogt, P. Ferrari, C. Scho¨nholzer et al., “Prophylactic hemodialysis after radiocontrast media in patients with renal insuﬃciency is potentially harmful,” American Journal of Medicine, vol. 111, no. 9, pp. 692–698, 2001. [109] T. Lehnert, E. Keller, K. Gondolf et al., “Eﬀect of haemodial- ysis after contrast medium administration in patients with renal insuﬃciency,” Nephrology Dialysis Transplantation, vol. 13, no. 1, pp. 358–362, 1998. [110] G. Marenzi, G. Lauri, J. Campodonico et al., “Comparison of two hemoﬁltration protocols for prevention of contrast- induced nephropathy in high-risk patients,” American Jour- nal of Medicine, vol. 119, no. 2, pp. 155–162, 2006. [111] G. Marenzi, I. Marana, G. Lauri et al., “The prevention of radiocontrast-agent-induced nephropathy by hemoﬁltra- tion,” New England Journal of Medicine, vol. 349, no. 14, pp. 1333–1340, 2003. [112] D. J. Spinosa, J. F. Angle, K. D. Hagspiel, J. A. Kern, G. D. Hartwell, and A. H. Matsumoto, “Lower extremity arteriography with use of iodinated contrast material or gadodiamide to supplement CO2 angiography in patients with renal insuﬃciency,” Journal of Vascular and Interven- tional Radiology, vol. 11, no. 1, pp. 35–43, 2000. [113] C. M. Erley, B. D. Bader, E. D. Berger et al., “Gadolinium- based contrast media compared with iodinated media